Short Interest in Medicus Pharma Ltd (NASDAQ:MDCX) Increases By 171.5%

Medicus Pharma Ltd (NASDAQ:MDCX) was the recipient of a significant growth in short interest in July. As of July 15th, there was short interest totaling 2,838,930 shares, a growth of 171.5% from the June 30th total of 1,045,598 shares. Approximately 5.5% of the company’s stock are short sold. Based on an average trading volume of 1,143,133 shares, the days-to-cover ratio is currently 2.5 days.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on MDCX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Medicus Pharma in a research note on Wednesday, July 8th. Roth Capital assumed coverage on shares of Medicus Pharma in a research report on Tuesday, April 21st. They set a “buy” rating on the stock. Finally, D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Medicus Pharma in a report on Monday, April 20th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Medicus Pharma presently has an average rating of “Hold” and a consensus price target of $9.00.

Medicus Pharma Stock Performance

Medicus Pharma stock traded down $0.05 during mid-day trading on Monday, reaching $0.32. 3,253,793 shares of the company were exchanged, compared to its average volume of 3,624,572. The firm has a market cap of $18.03 million, a P/E ratio of -0.12 and a beta of -0.05. The business has a fifty day moving average of $0.37 and a 200 day moving average of $0.65. Medicus Pharma has a 12-month low of $0.25 and a 12-month high of $3.05.

Medicus Pharma (NASDAQ:MDCX) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.13). Sell-side analysts predict that Medicus Pharma will post -0.51 EPS for the current year.

Institutional Trading of Medicus Pharma

Institutional investors have recently modified their holdings of the company. Armistice Capital LLC purchased a new position in shares of Medicus Pharma in the 4th quarter worth approximately $2,771,000. Private Advisor Group LLC boosted its stake in Medicus Pharma by 36.8% in the first quarter. Private Advisor Group LLC now owns 240,055 shares of the company’s stock valued at $110,000 after acquiring an additional 64,560 shares in the last quarter. Jane Street Group LLC purchased a new position in Medicus Pharma in the fourth quarter worth $92,000. Wilmington Savings Fund Society FSB grew its holdings in Medicus Pharma by 100.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock worth $78,000 after purchasing an additional 25,622 shares during the last quarter. Finally, May Hill Capital LLC increased its position in shares of Medicus Pharma by 100.0% during the fourth quarter. May Hill Capital LLC now owns 35,622 shares of the company’s stock worth $55,000 after purchasing an additional 17,811 shares in the last quarter.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.